Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials
Axel Hauschild(University Hospital Schleswig-Holstein), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Célèste Lebbé(Inserm), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Dirk Schadendorf(National Center for Tumor Diseases), T Haas(Novartis (United States)), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Eduard Gasal, Richard Kefford(Broad Institute), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Antoni Ribas(University of California, Los Angeles), Bijoyesh Mookerjee(Novartis (United States)), Felix Kiecker(Humboldt-Universität zu Berlin), Christian U. Blank(The Netherlands Cancer Institute), Lev Demidov(Heidelberg University), Michael Millward(University of Western Australia), Anthony M. D’Amelio(Novartis (United States))
Cited by 69
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k